Mark Campbell

Background and experience

The primary focus of my position is the scientific and operational management of our murine metabolic and/or cardio metabolic phenotyping programmes. This involves ongoing assessment and optimisation of the teams’ resources (financial, technological, and human) required to carry out our research according to appropriate timelines and defined budgetary targets.

Through the use and dissemination of scientific evidence, appropriate metrics, key performance indicators, knowledge, and experience, my role is involved in the identification and mitigation of process failures in order to improve workflow and productivity, ensure incorporation of best practices, maximize research quality, and ultimately oversee and increase the capabilities for the scientific output of the team.

Current research interests

Key interests in the context of obesity, diabetes and non-alcoholic fatty liver disease:

• Characterisation of murine metabolic phenotypes
• Adipose tissue biology
• Mitochondrial dysfunction

Key publications

1. Pellegrinelli, V., Figueroa-Juarez, E., Samuelson, I., U-Din, M., Rodriguez-Fdez, S., Virtue, S., Leggat, J., Cubuk, C., Peirce, V.J., Niemi, T. and Campbell, M., 2023. Defective extracellular matrix remodeling in brown adipose tissue is associated with fibro-inflammation and reduced diet-induced thermogenesis. Cell Reports, 42(6).
2. Dysregulation of macrophage PEPD in obesity determines adipose tissue fibro-inflammation and insulin resistance. V Pellegrinelli, S Rodriguez-Cuenca, C Rouault, E Figueroa-Juarez, H Schilbert, S Virtue, JM Moreno-Navarrete, G Bidault, MC Vázquez Borrego, AR Dias, B. Pucker, M Dale, M Campbell, S Carobbio, YH Lin, M. Vacca, J Aron-Wisnewsky, S Mora, MM Masiero, A Emmanouilidou, S Mukhopadhyay, G Dougan, M den Hoed, R JF Loos, JM Fernández-Real, D Chiarugi, K Clément, A Vidal-Puig. Nature Metabolism 2022;4(4):476-494.
3. Allostatic hypermetabolic response in PGC1α/β heterozygote mouse despite mitochondrial defects. Rodriguez-Cuenca S, Lelliot CJ, Campbell M, Peddinti G3, Martinez-Uña M, Ingvorsen C, Dias AR, Relat J, Mora S, Hyötyläinen T, Zorzano A, Oresic M, Bjursell M, Bohlooly-Y M, Lindén D and Vidal-Puig, A. FASEB J. 2021 Sep;35(9):e21752.
4. Rodriguez-Cuenca S, Carobbio S, Barceló-Coblijn G, Prieur X, Relat J, Amat R, Campbell M, Dias AR, Bahri M, Gray SL, Vidal-Puig A. P465L-PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates. Diabetes Obes Metab. 2018
5. Rodriguez-Cuenca S, Pellegrinelli V, Campbell M, Oresic M, Vidal-Puig A. Sphingolipids and glycerophospholipids - The "ying and yang" of lipotoxicity in metabolic diseases. Prog Lipid Res. 2017